Literature DB >> 22912917

Hyperinsulinemia and insulin resistance in a patient with type 2 diabetes complicated with myelofibrosis.

Hidetaka Hamasaki1, Shuichi Mishima, Hidekatsu Yanai.   

Abstract

Inflammation induces insulin resistance and hyperinsulinemia due to elevation of serum cytokines such as tumor necrosis factor-α and interleukins. Chronic myeloproliferative diseases including myelofibrosis show higher serum interleukin levels than healthy subjects, which has been suggested to be the useful markers for disease activity. However, an association between myelofibrosis and insulin resistance has not ever been discussed anywhere. Here we report a case of type 2 diabetes showing remarkable hyperinsulinemia and insulin resistance possibly due to myelofibrosis.

Entities:  

Keywords:  Cytokines; Hepatosplenomegaly; Hyperinsulinemia; Insulin resistance; Myelofibrosis

Year:  2012        PMID: 22912917      PMCID: PMC3423639          DOI: 10.4239/wjd.v3.i8.156

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  6 in total

1.  Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.

Authors:  Katerina E Panteli; Eleftheria C Hatzimichael; Paraskevi K Bouranta; Afroditi Katsaraki; Konstantinos Seferiadis; Justin Stebbing; Konstantinos L Bourantas
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

Review 2.  Metabolic memory in diabetes--focus on insulin.

Authors:  Derek LeRoith; Vivian Fonseca; Aaron Vinik
Journal:  Diabetes Metab Res Rev       Date:  2005 Mar-Apr       Impact factor: 4.876

Review 3.  Inflammation and insulin resistance.

Authors:  Steven E Shoelson; Jongsoon Lee; Allison B Goldfine
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

4.  Glucagon and insulin metabolism in a portal-hypertensive rat model.

Authors:  E Sikuler; J Polio; R J Groszmann; R Hendler
Journal:  Am J Physiol       Date:  1987-08

5.  Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.

Authors:  Mohannad Abu-Hilal; Jayant Tawaker
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

Review 6.  Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation.

Authors:  Niccolò Lanati; Enzo Emanuele; Natascia Brondino; Diego Geroldi
Journal:  Curr Vasc Pharmacol       Date:  2010-01       Impact factor: 2.719

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.